Correlation Between LTC4S -444 A>C Polymorphism and Susceptibility to Asthma: A Meta-analysis and Trial Sequential Analysis
LTC4S polymorphism and susceptibility to asthma
Abstract
Background: This study aims to uncover the potential correlation between LTC4S -444 A>C polymorphism and susceptibility to asthma.
Methods: Literatures reporting the correlation between LTC4S -444 A>C polymorphism and susceptibility to asthma published before 1st June, 2019 were searched in PubMed, Embase, Cochrane, Wanfang and CNKI. Eligible literatures were enrolled and their data were extracted. OR and its 95%CI were calculated for assessing the correlation between LTC4S -444 A>C polymorphism and susceptibility to asthma. The included data were weighted by an inverse variance and then analyzed by a fixed or random effects model. Heterogeneity test and sensitivity analysis were performed on the enrolled reports. STATA12.1 and TSA (trial sequential analysis) were utilized for analyses.
Results: Fifteen studies involving 3,791 asthma patients and 2,185 healthy controls were enrolled. No significant correlation was found between the LTC4S -444 A>C polymorphism and susceptibility to asthma according to the results of different models ((Dominant model (D): OR=1.10, 95%CI=0.98-1.23; Recessive model (R): 1.07, 0.84-1.36; Homozygous model (Homo): 1.11, 0.87-1.41; Heterozygous model (Hetero): 1.10, 0.98-1.24; Allele model (A): 1.07, 0.98-1.18). Subgroup analyses carried out in Asian and Caucasian population, as well as in population-based and hospital-based controls obtained the same conclusions.
Conclusions: No significant correlation is identified between the LTC4S -444 A>C polymorphism and susceptibility to asthma. Researches with high-quality and large sample size are required for further validation in multi-center hospital.
References
1. Mims JW. Asthma: definitions and pathophysiology. Int Forum Allergy Rh 2015; 5 Suppl 1: S2-6.
2. Chung KF. Clinical management of severe therapy-resistant asthma. Expert Rev Resp Med 2017; 11(5): 395-402.
3. Martin AA, Fainardi V, Saglani S. Severe therapy resistant asthma in children: translational approaches to uncover sub-phenotypes. Expert Rev Resp Med 2017; 11(11): 867-74.
4. Zinellu E, Piras B, Ruzittu G, Fois SS, Fois AG, Pirina P. Recent Advances in Inflammation and Treatment of Small Airways in Asthma. Int J Mol Sci 2019; 20(11):
5. Nagano T, Katsurada M, Dokuni R, Hazama D, Kiriu T, Umezawa K, et al. Crucial Role of Extracellular Vesicles in Bronchial Asthma. Int J Mol Sci 2019; 20(10):
6. Matera MG, Calzetta L, Rogliani P, Cazzola M. Monoclonal antibodies for severe asthma: Pharmacokinetic profiles. Resp Med 2019; 153: 3-13.
7. Kaplan A, Hardjojo A, Yu S, Price D. Asthma Across Age: Insights From Primary Care. Front Pediatr 2019; 7: 162.
8. Shaker M, Greenhawt M. A primer on cost-effectiveness in the allergy clinic. Ann Allerg Asthma Im 2019; 123(2): 120-8.
9. Shaker M, Greenhawt M. Providing cost-effective care for food allergy. Ann Allerg Asthma Im 2019; 123(3): 240-8.
10. Barnthouse M, Jones BL. The Impact of Environmental Chronic and Toxic Stress on Asthma. Clin Rev Allerg Immu 2019; 57(3): 427-38.
11. Perdijk O, Marsland BJ. The microbiome: toward preventing allergies and asthma by nutritional intervention. Curr Opin Immunol 2019; 60: 10-8.
12. Corren J. New Targeted Therapies for Uncontrolled Asthma. J Aller Cl Imm-Pract 2019; 7(5): 1394-403.
13. Carpaij OA, Burgess JK, Kerstjens H, Nawijn MC, van den Berge M. A review on the pathophysiology of asthma remission. Pharmacol Therapeut 2019; 201: 8-24.
14. Devi NS, Paragi-Vedanthi P, Bender A, Doble M. Common structural and pharmacophoric features of mPGES-1 and LTC4S. Future Med Chem 2018; 10(3): 259-68.
15. Ahmad S, Ytterberg AJ, Thulasingam M, Tholander F, Bergman T, Zubarev R, et al. Phosphorylation of Leukotriene C4 Synthase at Serine 36 Impairs Catalytic Activity. J Biol Chem 2016; 291(35): 18410-8.
16. Berghea EC, Popa LO, Dutescu MI, Meirosu M, Farcasanu IC, Berghea F, et al. Association of Leukotriene C4 Synthase A-444C Polymorphism with Asthma and Asthma Phenotypes in Romanian Population. Maedica (Bucur) 2015; 10(2): 91-6.
17. Sanchez-Borges M, Acevedo N, Vergara C, Jimenez S, Zabner-Oziel P, Monzon A, et al. The A-444C polymorphism in the leukotriene C4 synthase gene is associated with aspirin-induced urticaria. J Invest Allerg Clin 2009; 19(5): 375-82.
18. Wu YH, Liu CT, Wang K, Geng YM. [The relevance of leukotriene C(4) synthase gene A (-444) C polymorphism to clinical responsiveness to montelukast in patients with asthma]. Zhonghua Jie He He Hu Xi Za Zhi 2008; 31(11): 806-10.
19. Sayers I, Barton S, Rorke S, Beghe B, Hayward B, Van Eerdewegh P, et al. Allelic association and functional studies of promoter polymorphism in the leukotriene C4 synthase gene (LTC4S) in asthma. Thorax 2003; 58(5): 417-24.
20. Isidoro-Garcia M, Davila I, Moreno E, Lorente F, Gonzalez-Sarmiento R. Analysis of the leukotriene C4 synthase A-444C promoter polymorphism in a Spanish population. J Allergy Clin Immun 2005; 115(1): 206-7.
21. Sanak M, Pierzchalska M, Bazan-Socha S, Szczeklik A. Enhanced expression of the leukotriene C(4) synthase due to overactive transcription of an allelic variant associated with aspirin-intolerant asthma. Am J Resp Cell Mol 2000; 23(3): 290-6.
22. Pawlik A, Juzyszyn Z, Gawronska-Szklarz B. N-acetyltransferase 2 (NAT2) polymorphism in patients with atopic asthma. Arch Med Res 2009; 40(4): 264-7.
23. Kedda MA, Shi J, Duffy D, Phelps S, Yang I, O'Hara K, et al. Characterization of two polymorphisms in the leukotriene C4 synthase gene in an Australian population of subjects with mild, moderate, and severe asthma. J Allergy Clin Immun 2004; 113(5): 889-95.
24. Park JS, Chang HS, Park CS, Lee JH, Lee YM, Choi JH, et al. Association analysis of cysteinyl-leukotriene receptor 2 (CYSLTR2) polymorphisms with aspirin intolerance in asthmatics. Pharmacogenet Genom 2005; 15(7): 483-92.
25. Asano K, Shiomi T, Hasegawa N, Nakamura H, Kudo H, Matsuzaki T, et al. Leukotriene C4 synthase gene A(-444)C polymorphism and clinical response to a CYS-LT(1) antagonist, pranlukast, in Japanese patients with moderate asthma. Pharmacogenetics 2002; 12(7): 565-70.
26. Pan MM, Sun TY, Zhang HS. Association between leukotriene C4 synthase A-444C polymorphism and asthma in Chinese Han population in Beijing. Chinese Med J-Peking 2006; 119(21): 1834-8.
27. Moissidis I, Chinoy B, Yanamandra K, Napper D, Thurmon T, Bocchini JJ, et al. Association of IL-13, RANTES, and leukotriene C4 synthase gene promoter polymorphisms with asthma and/or atopy in African Americans. Genet Med 2005; 7(6): 406-10.
28. Sanz C, Isidro-Garcia M, Davila I, Moreno E, Laffond E, Lorente F. Analysis of 927T> C CYSLTRI and -444A > C LTC4S polymorphisms in patients with asthma. J Invest Allerg Clin 2006; 16(6): 331-7.
29. Kang MJ, Kwon JW, Kim BJ, Yu J, Choi WA, Shin YJ, et al. Polymorphisms of the PTGDR and LTC4S influence responsiveness to leukotriene receptor antagonists in Korean children with asthma. J Hum Genet 2011; 56(4): 284-9.
30. Choi JH, Kim SH, Bae JS, Yu HL, Suh CH, Nahm DH, et al. Lack of an association between a newly identified promoter polymorphism (-1702G > A) of the leukotriene C4 synthase gene and aspirin-intolerant asthma in a Korean population. Tohoku J Exp Med 2006; 208(1): 49-56.
31. Xie Y, Yang ZZ, Chai BC: Cysteinyl leukotrienes receptor 1 and leukotriene C4 synthetase genetic polymorphism in asthmatic children (Chinese). Lin Chuang Yi Xue 2010; 30: 40e43.
32. Nakagawa S, Noble DW, Senior AM, Lagisz M. Meta-evaluation of meta-analysis: ten appraisal questions for biologists. Bmc Biol 2017; 15(1): 18.
33. Lee YH. An overview of meta-analysis for clinicians. Korean J Intern Med 2018; 33(2): 277-83.
Copyright (c) 2023 Delin Wu, Yan Liu, Najuan Cui, Yan Zhu, Yuna Liu, Sidao Zheng, Shaohua Wang
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.